Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849856 | 0.90 | SMN1; SMN2 (0.73) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1848388 | 0.89 | L3MBTL1 (0.72) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1723416 | 0.86 | RAB9A (0.68) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL28154099 | 0.85 | TSHR (0.68) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL838607 | 0.83 | RAB9A (0.68) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4775518 | 0.82 | RAB9A (0.83) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13010738 | 0.82 | SMN1; SMN2 (0.57) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL22540419 | 0.82 | MAPT (0.59) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17450654 | 0.81 | RAB9A (0.66) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12101150 | 0.81 | RAB9A (0.66) | RAB9AMAPTNPC1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402783-B1 | 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| CN-102171213-A | Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity | ASTRAZENECA AB | 2011-08-31 | — | — | CN | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | RAB9A 168/4885MAPT 1744/4885NPC1 1601/4885 |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | RAB9A 217/4885MAPT 1748/4885NPC1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.